239 related articles for article (PubMed ID: 14660716)
1. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.
Kamel EM; Zwahlen D; Wyss MT; Stumpe KD; von Schulthess GK; Steinert HC
J Nucl Med; 2003 Dec; 44(12):1911-7. PubMed ID: 14660716
[TBL] [Abstract][Full Text] [Related]
2. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy.
Dizendorf EV; Baumert BG; von Schulthess GK; Lütolf UM; Steinert HC
J Nucl Med; 2003 Jan; 44(1):24-9. PubMed ID: 12515872
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study.
Bradley JD; Dehdashti F; Mintun MA; Govindan R; Trinkaus K; Siegel BA
J Clin Oncol; 2004 Aug; 22(16):3248-54. PubMed ID: 15310768
[TBL] [Abstract][Full Text] [Related]
4. 18F-fluorodeoxyglucose positron emission tomography in small-cell lung cancer.
Zhao DS; Valdivia AY; Li Y; Blaufox MD
Semin Nucl Med; 2002 Oct; 32(4):272-5. PubMed ID: 12524651
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
Kalff V; Hicks RJ; MacManus MP; Binns DS; McKenzie AF; Ware RE; Hogg A; Ball DL
J Clin Oncol; 2001 Jan; 19(1):111-8. PubMed ID: 11134203
[TBL] [Abstract][Full Text] [Related]
6. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET).
Kut V; Spies W; Spies S; Gooding W; Argiris A
Am J Clin Oncol; 2007 Feb; 30(1):45-50. PubMed ID: 17278894
[TBL] [Abstract][Full Text] [Related]
7. Impact of 18F-fluorodeoxyglucose positron emission tomography in the staging and treatment response assessment of extra-pulmonary small-cell cancer.
Gregory DL; Brennan SM; Stillie A; Herschtal A; Hicks RJ; MacManus MP; Ball DL
J Med Imaging Radiat Oncol; 2010 Apr; 54(2):100-7. PubMed ID: 20518871
[TBL] [Abstract][Full Text] [Related]
8. Staging non-small cell lung cancer with whole-body PET.
Marom EM; McAdams HP; Erasmus JJ; Goodman PC; Culhane DK; Coleman RE; Herndon JE; Patz EF
Radiology; 1999 Sep; 212(3):803-9. PubMed ID: 10478250
[TBL] [Abstract][Full Text] [Related]
9. Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer.
Shen YY; Shiau YC; Wang JJ; Ho ST; Kao CH
Anticancer Res; 2002; 22(2B):1257-64. PubMed ID: 12168935
[TBL] [Abstract][Full Text] [Related]
10. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
11. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer.
Pandit N; Gonen M; Krug L; Larson SM
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):78-84. PubMed ID: 12483413
[TBL] [Abstract][Full Text] [Related]
13. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience.
Blum R; MacManus MP; Rischin D; Michael M; Ball D; Hicks RJ
Am J Clin Oncol; 2004 Apr; 27(2):164-71. PubMed ID: 15057156
[TBL] [Abstract][Full Text] [Related]
14. Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer.
Lee HY; Chung JK; Jeong JM; Lee DS; Kim DG; Jung HW; Lee MC
Ann Nucl Med; 2008 May; 22(4):281-6. PubMed ID: 18535878
[TBL] [Abstract][Full Text] [Related]
15. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW
Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
[TBL] [Abstract][Full Text] [Related]
16. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study.
Chin R; McCain TW; Miller AA; Dunagan DP; Acostamadiedo J; Douglas Case L; Harkness BA; Adler LP; Haponik EF
Lung Cancer; 2002 Jul; 37(1):1-6. PubMed ID: 12057859
[TBL] [Abstract][Full Text] [Related]
17. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer.
Brink I; Schumacher T; Mix M; Ruhland S; Stoelben E; Digel W; Henke M; Ghanem N; Moser E; Nitzsche EU
Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1614-20. PubMed ID: 15258700
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K
Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093
[TBL] [Abstract][Full Text] [Related]
20. Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma.
Yen RF; Hong RL; Tzen KY; Pan MH; Chen TH
J Nucl Med; 2005 May; 46(5):770-4. PubMed ID: 15872349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
